Member Info for KonarA

I can't remember his exact words, but Sath made a point of stressing that there were a number of realistic revenue generating events that could extend the cash runway. In other words.. they know where the money is coming from and it isn't a raise.

And interesting "read between the lines" for me, was that Lindy referenced the trial taking place "Here and in the UK". She is clearly in the US at the moment.

"Registration trial may not be required if regulators decide SCIB meets an unmet need but Scancell are preparing for a trial. My understanding is that they expect to go to trial"

Not 100% correct. A subsequent trial WILL be necessary.. its just whether it will achieve breakthrough based on the first phase of that subsequent trial, without needing to expand to the full phase 3 prior to registration.

I was also initially optimistic about the wording used in the title of her presentation, until I realised it was the same title for a presentation she gave at the beginning of the year, with no new clinical data.

Even if the podcast were recorded recently, i don't think Lindy would disclose additional information (even recruitment rates) than has been covered under a RNS. I don't expect the "number of people recruited" is an accurate reflection of the current position.

Wouldn't be a discussion board without some disagreement

But on one thing we must surely be able to agree on - we have no more patient data beyond those dates that I posted. And when we are talking about trial results, it's patient data that we are really interested in.

On that we can agree to disagree. They are just trial updates. They are not clinical updates.

@bojo - thanks - but tbf my first post didn't explicitly state clinical, BUT it was in a thread on Phase 2 clinical updates... so i felt it was self-explanatory.

"Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces today it has two further responders on the SCOPE study, bringing the number of responders to 11 out of 13 patients. This is an objective response rate (ORR) of 85%." - November 23

The data below was not new clinical data in Jan.

I know what i posted... i am happy to be corrected. Can you please link me to where there is a clinical update since then, as I am not aware of one.

@C11 can you link me where there is clinical updates?

I know there has been a lot of talking recently about being well overdue a clinical update, but I remain of the opinion that they are saving it all for a conclusive headline grabbing release, once all the data is in.

At a Q&A session previously (think it was the AGM) Lindy was asked if there would be regular clinical updates. She responded along the lines of "We won't be releasing specific patient details as that remains patient confidential. But this is an open label study, so we can give regular updates on all the patients" (not a direct quote - but that was the general gist of it).

We haven't had a SCIB1 update since (i think) November 2023 and Moditope since (again - i think) February 2023. My gut feel is if they haven't released any data in all that time, its for a reason, and they are close enough to trial end now that it would seem pointless releasing the data ahead of a conclusion.

... or maybe not. Same title as the presentation she gave in April at the 8th Immuno-Oncology Summit Europe 2024.

https://www.lse.co.uk/rns/SCLP/presenting-at-the-annual-immuno-oncology-summit-5d6cf183cnxln62.html

We didn't get a market update then.

16th Oct looks more promising

@violindog - Lindy didn't give iSCIB1 a 90% chance of working.

The statisticians gave SCIB1 a greater than 90% chance of hitting its stage 2 end point (27/43 responders), based on the first stage 11/13 patients.

The 90% comment had nothing to do with iSCIB1

@Chester i don't imagine the recruitment has been linear (8/month). A number of those 22 recruited by July may have been patient's previously rejected for SCIB1 due to HLA type, meaning recruit may have been front loaded. They may already have the scan data for a lot of those 22 patients.

ORR of 70% is that starting point. That is the threshold for success as defined by the trial.

For years my preference was to build value through successful registration trials of multiple products in multiple indications.

But given just how far behind schedule we are with SCIB1 (it was originally intended to COMPLETE phase 2 in 2018), and how long I have had funds tied up in here, I would now prefer a outright purchase, even if for a lot lower than the long term potential of the science. At this stage, a bird in the hand would be valued.

100% this... they know the results and its full steam ahead.

Seems like yet more evidence that the company is well aware that the SCOPE study IS progressing to registration trial - both in terms of results to date and possibly funding.

Https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/2024/240730-scancell-appointment-of-cmo-press-release_final.pdf

Its not the link.. they published the wrong RNS. If you go on the actual RNS news feed from the stock exchange, it is the wrong release there. Someone at scancell (or advisers) FU.